



Mitchell P Levesque

Contact

Mitchell P Levesque

Publications (4)

Diem S, Risch M, Recher M, Risch L, Dummer R, Levesque M, Mangana J, Hillmann D, Niederer R, Berner F, Ali O, Bomze D, Fässler M, Flatz L. Immunoglobulin G and Subclasses as Potential Biomarkers in Metastatic Melanoma Patients Starting Checkpoint Inhibitor Treatment. *J Immunother* 2019; 42:89-93.

Fässler M, Jörgen M, Recher M, Risch L, Güsewell S, Risch M, Speiser D, Ludewig B, Levesque M, Dummer R, Siano M, Krolík M, Diem S, Mangana J, Hasan Ali O, Berner F, Bomze D, Ring S, Niederer R, Gil Cruz C, Pérez Shibayama C, Flatz L. Antibodies as biomarker candidates for response and survival to checkpoint inhibitors in melanoma patients. *J Immunother Cancer* 2019; 7:50.

Guenova E, Kaesler S, Thomas P, Mailhammer R, Ghoreschi K, Schäkel K, Amarov B, Eichner M, Schaller M, Clark R, Röcken M, Köberle M, Volz T, Levesque M, Skabytska Y, Hoetzenecker W, Weindl G, Sauer K, Tham M, Kim K, Park J, Seo J, Desislava I, Cozzio A, Biedermann T. IL-4 abrogates T(H)17 cell-mediated inflammation by selective silencing of IL-23 in antigen-presenting cells. *Proc Natl Acad Sci USA* 2015; 112:2163-8.

Guenova E, Hoetzenecker W, Rozati S, Levesque M, Dummer R, Cozzio A. Novel therapies for cutaneous T-cell lymphoma: what does the future hold?. *Expert Opin Investig Drugs* 2014; 23:457-67.

Projects (0)

No results found.

Kantonsspital St.Gallen

Rorschacher Strasse 95

CH-9007 St.Gallen

T: +41 71 494 11 11

support.forschung@kssg.ch